Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study

Timothy M Cox1*, Dominick Amato2, Carla EM Hollak3, Cecile Luzy4, Mariabeth Silkey4, Ruben Giorgino4, Robert D Steiner5 for the Miglustat Maintenance Study Group

Abstract

Background: Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in patients with stable type 1 Gaucher disease after enzyme therapy.

Methods: Adult type 1 Gaucher disease patients stabilized during at least 3 years of previous enzyme therapy were included in this 2-year, prospective, open-label non-inferiority study. The primary endpoint was percent change from baseline in liver volume. Secondary endpoints included changes in spleen volume, hemoglobin concentration and platelet count.

Results: Forty-two patients were enrolled (mean±SD age, 45.1±12.7 years; previous enzyme therapy duration 9.5±4.0 years). Median (range) exposure to miglustat 100 mg t.i.d. was 658 (3765) days. Twenty-one patients discontinued treatment prematurely; 13 due to adverse events, principally gastrointestinal. The upper 95% confidence limit of mean percent change in liver volume from baseline to end of treatment was below the non-inferiority margin of 10% (−1.1%; 95%CI −6.0, 3.9%). Mean (95%CI) changes in spleen volume, hemoglobin concentration and platelet count were 102 (24,180) mL, −0.95 (−1.38, −0.53) g/dL and −44.1 (−57.6, −30.7) ×109/L, respectively.

Conclusions: The primary efficacy endpoint was met; overall there was no change in liver volume during 24 months of miglustat therapy. Several patients showed a gradual deterioration in some disease manifestations, suggesting that miglustat could maintain clinical stability, but not in all patients. Miglustat demonstrated a predictable profile of safety and tolerability that was consistent with that reported in previous clinical trials and experience in clinical practice.

Trial registration: Clinicaltrials.gov identifier NCT00319046

Keywords: Gaucher disease, Miglustat, Enzyme therapy, Maintenance, Efficacy, Safety
**Introduction**

Type 1 Gaucher disease is an inherited lysosomal disorder caused by impaired activity of β-glucocerebrosidase, and accumulation of glucosylceramide in pathologic macrophages in the liver, spleen, bone marrow and, less frequently, the lungs [1,2]. The most common clinical variant is type 1 Gaucher disease, which is characterized by anemia, thrombocytopenia, hepatosplenomegaly and skeletal manifestations such as bone pain, osteopenia, fragility fractures and osteonecrosis [2-5].

Enzyme therapy (often mistakenly termed enzyme replacement therapy) with recombinant human β-glucocerebrosidase (imiglucerase [Cerezyme®], Genzyme Therapeutics; velaglucerase [VPRIV™], Shire plc) reduces organomegaly and improves hematologic and biochemical parameters in type 1 Gaucher disease [6,7]. However, enzyme therapy requires regular intravenous infusions, which are a lifestyle burden for some patients [8,9].

Miglustat (Zavesca®; Actelion Pharmaceuticals) is an orally active iminosugar which reversibly inhibits UDP-glucosylceramide synthase – the enzyme that catalyzes the rate-limiting step in glycosphingolipid biosynthesis. Miglustat was approved in Europe in 2002 and in the USA in 2003 for use as a substrate reduction therapy in adult patients with mild-to-moderate type 1 Gaucher disease for whom enzyme therapy is unsuitable or not a therapeutic option [10,11].

During developmental clinical trials, miglustat induced sustained reductions of liver and spleen volumes, with increased hemoglobin concentrations and platelet counts; the plasma activity of the biomarker, chitotriosidase, also decreased [12-15]. Similar effects have been observed in ‘real-world’ clinical practice settings [16,17]. It has also been suggested that miglustat improves cortical and trabecular bone mineral density (BMD) during 6 months to 2 years of therapy, and can reduce the frequency of bone pain in a sustained manner [18].

A randomized, open-label Phase II clinical trial evaluated the use of miglustat, given alone or in combination with enzyme therapy, in type 1 Gaucher disease patients stabilized by long-term treatment with imiglucerase [19]. However, equivocal beneficial effects on the disease, observed over a limited duration of assessment in a small number of patients, did not allow a definitive conclusion as to whether oral miglustat is effective in maintaining clinical stability in patients with type 1 Gaucher disease after they have received enzyme therapy. Further clinical trial data were requested by the European Medicines Association (EMA) to investigate this issue more fully, and a suitable study design was defined through subsequent consultation.

Here we report the findings of a study of miglustat as maintenance treatment in adult patients whose type 1 Gaucher disease had been controlled by enzyme therapy. As the inclusion of a placebo or non-drug arm was considered unethical for this patient population, the study was of an open-label, non-controlled design.

**Methods**

**Study design and patients**

This was a multicenter, international, open-label, Phase IIIb non-inferiority study comprising a 6-month screening period, a 24-month treatment period and a 28-day safety follow-up period. The primary objective was to evaluate the long-term effect of miglustat maintenance therapy on liver volume in adult patients with stable type 1 Gaucher disease who switched to miglustat from enzyme therapy. The secondary objectives were to examine the effects of miglustat on spleen volume and other type 1 Gaucher disease manifestations during long-term maintenance therapy. The safety and tolerability of miglustat was also assessed, including neurological and neuropsychological assessments.

Male and female patients aged at least 18 years with confirmed, stable type 1 Gaucher disease, who had undergone 3 or more years of enzyme therapy and had been on a stable enzyme dose for at least 6 months were included. Patients were required to have stable disease for 2 or more years before enrolment, defined by assessments during at least two appropriate time points confirming the following: stable organomegaly, with the last three liver and spleen volume assessments within 10% of the mean of these values (as assessed by magnetic resonance imaging [MRI] or computed X-ray tomography [CT]); a documented absence of symptomatic bone disease; mean hemoglobin level >11 g/dL; mean platelet count >100 × 10^9/L; stable chitotriosidase activity, with the last three values within 20% of these values.

The stability of disease in individual study participants was adjudicated at the beginning of the study by an independent Steering Committee comprising five clinical experts in Gaucher disease who were neither investigators nor directly involved in the conduct of the study. This Steering Committee also adjudicated cases of suspected disease worsening during the study, and carried out a final adjudication of all referred cases at the end of the study.

Patients were excluded if they had manifestations of neuronopathic Gaucher disease, were non-ambulatory or had symptomatic bone disease. Other reasons for exclusion included splenectomy before 18 years of age, documented peripheral polyneuropathy comprising suggestive symptoms, compatible clinical signs and electrodiagnosis, a history of lactose intolerance, diarrhea (>3 liquid stools per day for >7 days), or a history of gastrointestinal disorders.

All patients provided written informed consent for study entry. The protocol and management structure...
were reviewed and approved by Institutional Review Boards or Independent Ethics Committees, and the study was conducted in accordance with the principles and procedures outlined in the Declaration of Helsinki. This trial was registered on www.clinicaltrials.gov on April 26, 2006 (identifier # NCT00319046).

Treatment
All patients were prescribed oral miglustat 100 mg capsules three times daily throughout the 24-month treatment period, as specified in the prescribing information [11]. Dose reduction to 100 mg once or twice a day was permitted if patients experienced treatment-related diarrhea or other gastrointestinal symptoms, and this reduction was maintained until the symptoms subsided.

Efficacy endpoints
The primary efficacy endpoint was the mean percent change in liver volume from baseline to Month 24. Liver volume was assessed by MRI every 6 months. Mean change in spleen volume from baseline to Month 24 was determined as a secondary efficacy endpoint. Spleen and liver volume were measured centrally by a specialized imaging center (SYNARC, Sèvres, France), as well as locally at each study center. Hemoglobin concentration and platelet count were also assessed locally during each clinic visit as secondary efficacy endpoints. The disease biomarker, chitotriosidase activity, was measured at a central laboratory in plasma samples obtained at all visits during the treatment period.

Mean change in the bone marrow burden (BMB) score from baseline to Month 24 was measured as a secondary efficacy endpoint based on the sum of scores from standardized semi-quantitative MRI-based assessments of bone marrow infiltration in axial (lumbar spine) and peripheral (femoral) sites at baseline, Month 12 and Month 24. Scores from 1 to 8 were assigned at each skeletal site, giving a maximum total of 16; higher scores represent more severe bone marrow infiltration. BMB scores were assessed locally at each study center (when possible), as well as centrally by a specialized imaging center (SYNARC) using published methods [20].

The proportion of patients that worsened was also determined. If investigators suspected disease worsening, the Steering Committee was asked to adjudicate as to whether, on the basis of the available clinical data, the patient had worsening of their disease. The following pre-defined criteria were taken as potential signals of disease worsening: increase in liver volume ≥10% from baseline; increase in spleen volume ≥10% from baseline; hemoglobin concentration decreased ≥1 g/dL from baseline; reduction in platelet count at two consecutive laboratory evaluations (according to pre-defined criteria); any clinical signs or symptoms (e.g. documented bone crisis) or change in relevant biomarkers (e.g. increase in chitotriosidase activity or changes in serum ferritin, ACE or TRAP) that suggested disease worsening in the investigator’s opinion. Confirmation of disease worsening by the Steering Committee required consistent clinical and biological documentation so that an isolated signal may not have been considered sufficient to confirm disease worsening; agreement in each case was reached by consensus.

When disease worsening was confirmed by the Steering Committee, miglustat was discontinued and enzyme therapy was reintroduced at a dose considered most appropriate by the investigator. Patients who discontinued treatment before Month 24 were allowed to remain in the study and underwent the remaining assessments. In cases of ‘suspected disease worsening’, where worsening of a patient’s disease was suspected by the Steering Committee but not confirmed by further clinical evaluation, additional information and/or assessments were requested. Under these circumstances, miglustat was continued until a final decision was reached. In cases where worsening of the disease was suspected by the investigator but not confirmed by the Steering Committee, treatment with miglustat could be continued until Month 24. A final adjudication on disease worsening based on all available data (including central laboratory imaging findings) was carried out at the end of the study, and the reported numbers of patients with clinical worsening is based on this final adjudication.

Additional analysis: maintenance of therapeutic goals
An additional analysis of the achievement of accepted type 1 Gaucher disease therapeutic goals in patients who completed 24 months of miglustat treatment was also conducted. While not defined a priori, this analysis did not formally constitute a post-hoc analysis as it was included in the statistical analysis plan before database closure. Therapeutic goals were defined as previously described [21].

Safety and tolerability
Treatment-emergent adverse events (i.e. all adverse events occurring in enrolled patients who received at least one dose of study medication) and serious adverse events were recorded throughout the study. Standard laboratory measurements including hemoglobin, platelet counts, biochemistry (including vitamins B12 and B1), and serum protein electrophoresis were examined in blood samples taken at each clinic visit.

Rigorous testing for peripheral neuropathy was performed in all patients by a trained, certified neurologist at each clinical site based on patients’ medical history and assessments of clinical signs and symptoms, as described previously [4]. All patients also underwent electrodagnostic assessments at baseline, including nerve conduction
velocity testing and electromyography [22-24]. If a patient presented new or aggravated clinical signs and/or symptoms that suggested possible peripheral neuropathy during the study, a repeat electrodiagnostic examination was carried out by the local neurologist to confirm the diagnosis. At the end of the study, electrodiagnostic data were evaluated centrally by an independent assessor. Diagnoses of peripheral neuropathy were assigned on the basis of compatible clinical signs and/or symptoms accompanied by compatible electrodiagnostic findings.

Neuropsychological assessments of cognitive function were also conducted by qualified personnel at baseline and every 6 months throughout the study. These comprised a battery of tasks derived from the CDR computerized cognitive assessment system, and assessed the following cognitive domains: simple reaction time; digit vigilance; choice reaction time; spatial working memory; numeric working memory; word recognition; picture recognition; Morse tapping [25,26]. Alertness and self-rated mood were also each evaluated using Bond-Lader visual analogue scales [27].

Statistical analysis
A sample size of 42 patients was agreed as appropriate to meet the objectives of the study with the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Relevant study populations were defined as follows: ‘all-enrolled population’ - all enrolled patients regardless of whether they received study drug; ‘full analysis population’ - all enrolled patients who received study drug and had ≥1 post-baseline value for the primary endpoint; ‘per protocol population’ - patients in the full analysis population who completed the 24-month treatment period and did not have major protocol deviations that might have affected the primary endpoint.

Based on the standard deviation (SD) of the percent change in liver volume during a previous randomized clinical trial with miglustat (9.2%) [19], a clinically relevant non-inferiority limit of a 10% increase in liver volume was selected for the primary endpoint of this study. The null hypothesis was that the mean change in liver volume from baseline to Month 24 was ≥10%. The alternative hypothesis was that there was no change in liver volume. The null hypothesis was rejected if the upper limit of the two-sided 95% confidence interval (CI) around the mean change in liver volume from baseline to Month 24 was <10%.

Mean percent change in liver volume was determined by analyzing all available liver volume data from the full analysis population using a one-sample t-test with no adjustments for covariates. For the 20 patients in the full analysis population who discontinued miglustat prematurely, the worst (greatest) post-baseline value for liver volume on treatment was carried forward to substitute the Month 24 value in an ‘end of treatment’ analysis.

A sensitivity analysis was performed by comparing results from the full analysis population with the same analyses applied to the per-protocol population.

No formal statistical testing was carried out for secondary efficacy endpoints (change in spleen volume, hemoglobin concentration and platelet count), as there was no hypothesis test defined a priori for any of these endpoints, which are hypothesis-generating as opposed to inferential. Absolute values at baseline and follow up, and change from baseline data were summarized from the full analysis population using mean, SD and 95% CI. Descriptive ‘end of treatment’ analyses were conducted using last observations carried forward to impute missing values from patients who discontinued miglustat prematurely. Changes in hematological parameters and organ volumes were compared to previously defined therapeutic goals for Gaucher disease (21). These goals have not been validated but they may serve as benchmarks for clinically important changes.

Results
Patients
Forty-two patients (22 male, 20 female) were enrolled from 21 February 2006 onwards from 16 centers in Australia, Brazil, Canada, Czech Republic, France, Netherlands, Spain, Taiwan, UK, and the USA. The trial ended on 22 June 2010. The mean (SD) age at enrolment was 45.1 (12.7) years, and age at diagnosis was 24.8 (15.0) years (Table 1). Patients had previously received enzyme therapy for an average of 9.5 years, and had received the same dose of enzyme therapy (median [range] 54.7 [5.2-130.7] IU/kg/month) for approximately 5 years.

Patients in the ‘all enrolled’ patient population displayed relatively mild disease at baseline, with normal mean (SD) liver volume (0.91 [0.22] multiples of normal [15]), only mild splenomegaly among non-splenectomized patients (3.13 [1.76] multiples of normal [15]), and normal hemoglobin concentrations and platelet counts (Table 1). Overall, 80% of patients had attained the therapeutic goals at baseline [28]. Most patients (33/42; 78.6%) had intact spleens.

All 42 enrolled patients received ≥1 dose of the study drug (‘all-enrolled population’) and 41 patients had ≥1 post-baseline assessment for the primary endpoint (full analysis population) (Figure 1). There were a total of 21 premature discontinuations from therapy during the study, most of which were due to adverse events (13 patients); one patient withdrew for administrative reasons and one patient withdrew consent. Six patients discontinued miglustat prematurely because of disease worsening as assessed on the basis of local laboratory and data.
The primary efficacy endpoint was achieved in both the splenectomized and non-splenectomized patient subgroups (Table 2). Mean absolute liver volumes in these subgroups remained below baseline throughout treatment.

Secondary efficacy
Analyses in this section are based on available data for the full analysis population. Mean absolute changes from baseline in spleen volume, hemoglobin concentration and platelet count up to Month 24 of miglustat therapy are summarized in Figures 2B–D. Individual patient efficacy findings are listed against gender and body weight in Table 3.

Overall, spleen volume among the 22 evaluable, non-splenectomized patients showed a mean (95% CI) increase of 102 (24, 180) mL by Month 24 from a mean (SD) baseline value of 510 (372) mL; the mean percent change by Month 24 was 23% (95% CI: 7, 39). Changes from baseline appeared maximal by Month 18.

There was a small mean (95% CI) decrease in hemoglobin concentration of 0.95 (-1.38, -0.53) g/dL at Month 24, from a mean (SD) baseline value of 14.8 (1.53) g/dL. The mean change from baseline was maximal by Month 18, and the mean (SD) hemoglobin concentration was 13.9 (1.55) g/dL at end of treatment.

Platelet count showed a mean (95% CI) decrease of 44 (-58, -31) × 10^9/L from a mean (SD) baseline value of 199 (96) × 10^9/L. Again, maximal changes from baseline were observed at Month 18. Baseline platelet counts were higher in splenectomized patients (mean [SD] 304 [137] × 10^9/L) than in non-splenectomized patients (mean [SD] 164 [38] × 10^9/L). Mean (95% CI) decreases in platelet counts from baseline to Month 24 were also greater in splenectomized patients (-66 [-111, -21] × 10^9/L) compared with the non-splenectomized subgroup (-37 [-48, -25] × 10^9/L). There were no reported episodes (adverse events) of bleeding or bruising in either subgroup during miglustat therapy.

Sensitivity analysis demonstrated consistent findings between the per-protocol population and the full analysis population for each key secondary endpoint.

Total BMB score evaluations from baseline to end of treatment were available from 21 patients in the full analysis population (15 non-splenectomized and 6 splenectomized). Overall, BMB scores showed a slight increase (worsening) during the study; the median (95% CI) absolute total BMB score increased from 5 (3, 7) at baseline to 7 (4, 11) at the end of treatment – a median (95% CI) increase of 3 (0, 4). Eleven patients showed an increase of ≥3 points. There was no change in median (95% CI)
BMB score in splenectomized patients (0 [−3, 5]; n = 6) at the end of treatment compared with a median (95% CI) increase of 3 (0, 7) among non-splenectomized patients (n = 15). These results are consistent with an increase in Gaucher cell infiltration in some of the splenectomized patients.

Plasma chitotriosidase activity determinations at baseline and end of treatment were available for 28 patients. Chitotriosidase activity showed marked inter-individual variability at baseline, despite all patients having mild, stable disease (range 17–5,863 nmoles/(mL*hr)). From a baseline median (95% CI) value of 963 (420, 1,872) nmoles/(mL*hr), there was a median (95% CI) increase of 1,173 (643, 2,834) nmoles/(mL*hr) at end of treatment. Analysis of changes in chitotriosidase activities between baseline and end of treatment for each patient revealed a median (range) within-patient percent change of +102% (−62% to 2334%).

A total of 20 cases were referred to the Steering Committee for adjudication of potential disease worsening, including 11 patients referred during the study and 9 cases referred at the final end-of-study adjudication. Thirteen patients were confirmed as having disease worsening. For the remaining seven patients who were referred with one or more signals of possible worsening, when considered alongside the overall clinical picture of the patient, together with the clinical relevance of the findings, the Steering Committee did not consider these

Figure 1 Patient disposition. *All enrolled population; †full analysis population; **all patients with at least one post-baseline liver assessment (≥6 months) were included in primary endpoint analysis, including 11 patients who discontinued miglustat treatment prematurely; ††some patients had more than one of the listed reasons for non-inclusion in the per-protocol analysis; †‡Patient had documented symptomatic bone disease at screening and represented a protocol violation. Note: secondary efficacy evaluations based on full analysis population included different numbers of patients subject to data availability.
Table 2 Baseline and change from baseline in liver volume during up to 24 months of miglustat therapy (primary analysis)

|                  | Non-splenectomized (N = 23) | Splenectomized (N = 9) | All (N = 32) |
|------------------|------------------------------|------------------------|--------------|
| Baseline absolute value (mL) | Mean ± SD 1742 ± 440 | 1857 ± 604 | 1775 ± 484 |
| End of treatment absolute value (mL) | Mean ± SD 1736 ± 353 | 1704 ± 470 | 1727 ± 382 |
| Absolute change from baseline (mL) | Mean | −6.4 | −152.6 | −47.5 |
|                  | 95% CI (−124, 111) | (−395, 90) | (−151, 56) |
| Percent change from baseline | Mean | 1.3 | −7.2 | −1.1 |
|                  | 95% CI (−4.6%, 7.3%) | (−16.6%, 2.2%) | (−6.0%, 3.9%) |

Data analysis based on full analysis population.

Figure 2 Absolute changes in primary and secondary efficacy parameters during 24 months of miglustat therapy (full analysis population). Changes from baseline in a) liver volume, b) spleen volume, c) hemoglobin concentration and d) platelet count. Data are mean absolute change from baseline (square points), with 95% confidence intervals (grey boxes) and minimum–maximum value ranges (solid vertical lines).
| Pt. # | Gender | Genotype | Body wt. (kg) | Tx duration (days) | Liver (MN) | Liver volume (mL) | Spleen (MN) | Spleen volume (mL) | Hb (g/dL) | Platelets (x 10^9/l) | Chito nmol/ (mL*hr) |
|-------|--------|----------|--------------|-------------------|-----------|------------------|-------------|-------------------|-----------|-----------------|------------------|
| 1     | M      | N370S/unknown | 102          | 71                | 1.05 – 0.94 | 1420 – 3.40 | 696 – 15.1 | 127 – 159         |           |                 |                  |
| 2     | M      | N370S/IVS 2 + 1 | 79.4         | 148               | 0.73 – 0.80 | 1545 – 2.19 | 373 – 14.0 | 233 – 151         |           |                 |                  |
| 3     | F      | R404C/C202R  | 59.8         | 734               | 0.72 – 0.91 | 1627 – 1.49 | 392 – 13.1 | 231 – 107         |           |                 |                  |
| 4     | F      | N370S/L444P  | 126          | 868               | 1.49 – 1.54 | 1785 – 3.47 | 371 – 14.3 | 233 – 151         |           |                 |                  |
| 5     | F      | N370S/unknown | 69.7         | 628               | 0.77 – 0.80 | 1100 – 2.91 | 335 – 13.5 | 211 – 107         |           |                 |                  |
| 6     | F      | N370S/L444P  | 86.3         | 75                | 1.02 – 1.02 | 2062 – 4.30 | 699 – 13.4 | 106 – 839         |           |                 |                  |
| 7     | M      | N370S/L444P  | 85.0         | 663               | 0.73 – 0.80 | 1545 – 2.19 | 373 – 14.0 | 233 – 151         |           |                 |                  |
| 8     | F      | N370S/EXG DEL | 48.0         | 245               | 1.49 – 1.54 | 1785 – 3.47 | 371 – 14.3 | 233 – 151         |           |                 |                  |
| 9     | F      | N370S/L444P  | 91.0         | 732               | 0.72 – 0.80 | 1100 – 2.91 | 335 – 13.5 | 211 – 107         |           |                 |                  |
| 10    | M      | N370S/N370S  | 71.0         | –                 | – – – – – | – | – | – | – | – | – |
| 11    | M      | N370S/N370S  | 70.5         | 729               | 0.72 – 0.80 | 1545 – 2.19 | 373 – 14.0 | 233 – 151         |           |                 |                  |
| 12    | F      | N370S/T134P  | 57.0         | 46.7              | 0.77 – 0.80 | 1100 – 2.91 | 335 – 13.5 | 211 – 107         |           |                 |                  |
| 13    | M      | N370S/N370S  | 76.3         | 3                 | 0.94 – 1.02 | 1798 – 2.21 | 338 – 16.1 | 187 – 53          |           |                 |                  |
| 14    | M      | N370S/K198E  | 70.1         | 190               | 1.01 – 1.04 | 1827 – 2.72 | 382 – 15.2 | 160 – 4978        |           |                 |                  |
| 15    | M      | N370S/84GG   | 83.6         | 515               | 1.49 – 1.20 | 3112 – 4.66 | 779 – 13.3 | 199 – 149         |           |                 |                  |
| 16    | F      | N370S/S107L  | 78.5         | 405               | 0.83 – 0.91 | 1627 – 1.49 | 392 – 13.1 | 231 – 107         |           |                 |                  |
| 17    | F      | N370S/D490H  | 81.2         | 109               | 1.02 – 1.02 | 2062 – 4.30 | 699 – 13.4 | 106 – 839         |           |                 |                  |
| 18    | F      | N370S/L444P  | 59.2         | 57.4              | 1.33 – 1.19 | 1964 – 2.91 | 344 – 13.5 | 211 – 107         |           |                 |                  |
| 19    | M      | N370S/84GG   | 74.7         | 696               | 0.78 – 0.72 | 1463 – 2.72 | 382 – 15.2 | 160 – 4978        |           |                 |                  |
| 20    | F      | N370/NK      | 51.5         | 112               | 1.04 – 1.02 | 1341 – 3.11 | 320 – 16.8 | 183 – 591         |           |                 |                  |
| 21    | F      | N370S/N370S  | 73.5         | 69.0              | 0.66 – 0.67 | 1220 – 1.44 | 211 – 13.8 | 160 – 80          |           |                 |                  |
| 22    | F      | N370S/crossover | 62.5        | 58.2              | 1.00 – 1.16 | 1562 – 3.57 | 447 – 16.4 | 161 – 2969        |           |                 |                  |
| 23    | F      | N370S/unknown | 82.5         | 68.5              | 0.93 – 1.00 | 1925 – 7.03 | 830 – 16.6 | 104 – 389         |           |                 |                  |
| 24    | F      | N370S/N370S  | 67.7         | 65.9              | 0.82 – 0.86 | 1391 – 2.00 | 270 – 16.4 | 226 – 27          |           |                 |                  |
| 25    | M      | N370S/1327TT | 72.0         | 720               | 1.22 – 1.22 | 2191 – 4.51 | 650 – 15.0 | 152 – 2658        |           |                 |                  |
| 26    | F      | N370S/REC NEIL | 61.0        | 510               | 1.05 – 1.06 | 1444 – 1.61 | 217 – 14.8 | 186 – 3500        |           |                 |                  |
| 27    | F      | N370S/L444P  | 55.9         | 568               | 1.12 – 1.25 | 1571 – 4.01 | 449 – 13.6 | 148 – 2897        |           |                 |                  |
| 28    | M      | N370S/1035INS | 93.7       | 87.7              | 1.02 – 1.15 | 2391 – 1.43 | 268 – 11.3 | 151 – 5863        |           |                 |                  |
| 29    | M      | ND           | 91.2         | 87.3              | 1.05 – 1.05 | 1847 – 6.67 | 1217 – 15.0 | 151 – 5863        |           |                 |                  |
| 30    | M      | ND           | 94.1         | 84.8              | 0.81 – 0.97 | 1745 – 2.40 | 413 – 16.8 | 158 – 3398        |           |                 |                  |
| 31    | M      | N370S/N370S  | 95.9         | 82.3              | 0.82 – 0.90 | 1964 – 1.43 | 268 – 11.3 | 151 – 5863        |           |                 |                  |
| 32    | M      | N370S/84999  | 71.2         | 79.8              | 0.92 – 0.75 | 1638 – 2.18 | 311 – 14.9 | 186 – 391         |           |                 |                  |
| 33    | F      | N370S/R257X  | 124          | 109               | 1.05 – 0.88 | 3274 – 2.18 | 311 – 14.9 | 229 – 44          |           |                 |                  |
### Table 3 Individual patient data and primary and secondary efficacy parameter findings (Continued)

| Patient ID | Sex | Mutation | Hb | Chito | BL | EOT | % MN | % ND | % SPX | % Tx | % WV | % BL | % EOT | % MN | % ND | % SPX | % Tx | % WV | % BL | % EOT | % MN | % ND | % SPX | % Tx | % WV | % BL | % EOT | % MN | % ND | % SPX | % Tx | % WV |
|------------|-----|----------|----|-------|----|-----|------|------|-------|------|------|------|------|------|------|-------|------|------|------|------|------|------|------|------|-------|------|------|-------|------|------|------|-------|------|------|
| 34* | F | N370S/unidentified | 113 | 109 | 725 | 0.63 | 0.64 | 1788 | 1733 | 1.74 | 2.96 | 394 | 642 | 13.6 | 14.6 | 223 | 135 | 1587 | 4118 |
| 35* | F | N370S/unidentified | 89.2 | 68.8 | 725 | 0.52 | 0.85 | 1152 | 1468 | 2.23 | 3.24 | 398 | 446 | 15.3 | 14.8 | 149 | 102 | 132 | 1002 |
| 36* | M | N370S/unidentified | 70.3 | 68.9 | 725 | 0.97 | 1.09 | 1704 | 1880 | 2.94 | 4.34 | 413 | 598 | 14.2 | 14.6 | 177 | 158 | 13834 |
| 37* | M | N370S/unknown | 76.0 | – | 140 | 0.75 | – | 1434 | – | 2.11 | – | 320 | – | 14.7 | 14.4 | 141 | 141 | 438 | 510 |
| 38* | F | 84GG/N370S | 65.0 | 62.5 | 732 | 0.72 | 0.92 | 1162 | 1439 | 3.24 | 3.72 | 422 | 465 | 16.8 | 15.1 | 136 | 106 | 98 | 1271 |
| 39* | M | N370S/84GG | 88.0 | 81.0 | 730 | 0.88 | 1.11 | 1932 | 2248 | SPX | – | SPX | – | 17.1 | 14.8 | 254 | 174 | 1940 | 10636 |
| 40* | F | L444P/NA | 54.4 | – | 22 | 0.81 | – | 1095 | – | 2.18 | – | 238 | – | 16.2 | – | 134 | – | – | – |
| 41* | M | N370S/N370S | 76.7 | – | 15 | 0.80 | – | 1538 | – | 1.37 | – | 210 | – | 15.9 | – | 232 | – | – | 38 |
| 42* | F | N370S/N370S | 58.5 | 58.0 | 231 | 1.01 | 0.98 | 1471 | 1424 | 2.35 | 2.54 | 275 | 294 | 12.6 | 12.9 | 214 | 207 | 17 | 21 |

* BL, baseline; Chito, chitotriosidase; EOT, end of treatment; Hb, hemoglobin; MN, multiples of normal; ND, not determined; SPX, splenectomy; Tx, treatment; WV, worst value. * Patients adjudicated as showing disease worsening; † patients within therapeutic goals at baseline who were assessed for maintenance of therapeutic goals; †† patients in whom therapeutic goals were adjudicated based on worst value (end-of-treatment) analysis. Dashes represent patients in whom useable data values were not available or analyses (i.e. therapeutic goals) were not possible.
particular signals sufficient to constitute disease worsening. On the basis of local assessment of organ volume, two of these seven patients had been adjudicated as worsened during the study; however, on the basis of standardized central readings, they were not confirmed as worsened at the end-of-study adjudication (patients 5 and 8 in Table 3).

**Maintenance of therapeutic goals**

Most patients in the full analysis population who were within therapeutic goals for key type 1 Gaucher disease parameters at baseline were maintained within goal up to Month 24. Thirty-two patients had a baseline and a post-baseline assessment for liver volume while on miglustat therapy, and 29/32 (91%) who were within goal at baseline remained within goal at Month 24. Of the three patients who were outside the goal at baseline, two were within the goal and one remained outside goal by the end of treatment. For other parameters, the numbers and proportions of patients with available data who were within goal at baseline and remained within goal at the end of treatment were: 20/21 (95%) for spleen volume; 33/35 (94%) for hemoglobin concentration; 29/34 (85%) for platelet count. Overall, 21/25 (84%) evaluable patients showed maintenance of disease stability across all disease parameters between baseline and the end of treatment.

**Safety and tolerability**

Safety and tolerability assessments did not reveal any new or unexpected safety findings, and were consistent with the known safety profile for miglustat [11]. Gastrointestinal disorders were the most frequently reported adverse events among the all-enrolled population, with intestinal disorders were the most frequently reported adverse events among the all-enrolled population, with gastrointestinal disturbances during miglustat therapy. The mean (SD) decrease in body weight among all patients between baseline and Month 24 was −7.7 (9.1) kg; median (range) decrease −4.6 (−39.0−0) kg.

Doses of miglustat were reduced from 100 mg t.i.d. to 100 mg b.i.d. in a total of three patients due to adverse events: two were due to gastrointestinal disturbances and one was due to cerebellar syndrome and hyperreflexia. Two of these patients later discontinued miglustat treatment prematurely, and their adverse events resolved with no clinical sequelae. One patient (with dose reduction due to diarrhea) went on to complete the study.

Thirteen out of 42 (31%) patients in the all-enrolled population discontinued miglustat therapy on account of adverse events that did not indicate worsening of their disease. Diarrhea and tremor were associated with discontinuations in 7/42 (17%) and 3/42 (7%) patients, respectively. Abdominal discomfort and abdominal distension were associated with discontinuations in 1 patient each. Most discontinuations related to adverse events occurred early during miglustat therapy: eight patients discontinued miglustat before Month 6, and two others between Months 6 and 12.

A further 5/42 (11.9%) patients discontinued miglustat therapy prematurely due to adverse events that may have been indicative of disease worsening according to protocol-defined criteria. These included increased chitotriosidase activity, decreased platelet count, decreased hemoglobin and splenomegaly. The reason for early discontinuation of miglustat therapy in these patients was recorded as ‘disease worsening’ in accordance with the study protocol in order to differentiate discontinuations due to tolerability issues from those required by the disease worsening criteria (see ‘Secondary efficacy section’); one patient was discontinued due to ‘disease worsening’ criteria without any corresponding adverse event being recorded.

All 42 patients had a baseline electrodiagnostic assessment, among whom three (7.1%) were diagnosed with mononeuropathy. Seven (16.7%) had minor electrodiagnostic abnormalities without clinical evidence of peripheral neuropathy, and five (12%) had electrodiagnostic abnormalities compatible with peripheral neuropathy. During the study, one of the seven patients with minor electrodiagnostic abnormalities but no clinical signs or symptoms of peripheral neuropathy at baseline developed a mild sensorimotor neuropathy that was not attributed to the study medication. This patient was

| Table 4 Treatment-emergent adverse events* during 24 months of miglustat therapy (all-enrolled population) |
|--------------------------------------------------|------------------|-----------|-----------|
| **Adverse event** | **Incidence (N = 42)** |
|--------------------|------------------|-----------|
| Diarrhea           | 31/42 (74)       |
| Flatulence         | 21/42 (50)       |
| Tremor             | 15/42 (36)       |
| Headache           | 9/42 (21)        |
| Paresthesia        | 9/42 (21)        |
| Fatigue            | 8/42 (19)        |
| Dizziness          | 7/42 (17)        |
| Arthralgia         | 6/42 (14)        |
| Weight decreased   | 6/42 (14)        |
| Abdominal discomfort| 5/42 (12)      |
| Hypoesthesia       | 5/42 (12)        |

*Adverse events with ≥10% incidence.
found to have vitamin B₁₂ deficiency, which was treated, and miglustat was continued without ill effect.

Neuropsychological investigations indicated no signs of cognitive deterioration associated with miglustat treatment. There was no consistent or progressive decline among the various neurocognitive tests.

**Discussion**

Oral treatment with miglustat for 24 months prevented pathological storage in liver as evidenced by the maintenance of liver size. The mean percent change in liver volume from baseline during 24 months of miglustat therapy (-1.1) was well within the pre-defined non-inferiority limit of 10%, and thus the primary efficacy endpoint of this 24-month, open-label non-inferiority study was met. In addition, all patients who were within the proposed therapeutic goal for liver volume at baseline were maintained within this goal throughout the study [21]. Liver volume was therefore maintained in patients with stable type 1 Gaucher disease who changed to miglustat after previous long-term enzyme therapy.

Change in liver volume has been recommended as a consistent clinical indicator of disease course and treatment effects in type 1 Gaucher disease as it does not tend to show the degree of inter-patient variability seen with other key disease parameters [28]. Liver volume or ratio has been assessed as the primary efficacy endpoint in a number of previous clinical trials alone or in combination with spleen volume [15,19,29], and was chosen following detailed discussions with the EMA at the time of trial design. Moreover, the analytical approach adopted in this study allowed an objective, quantitative assessment of this endpoint.

Inclusion of a placebo arm was considered unethical and impracticable in this treatment and patient setting, which is unfortunate as the absence of a suitable control group prevents a robust evaluation of the effects of miglustat in patients who have already had the benefit of enzyme therapy. Previous data indicate that a 2-year treatment interruption would carry a risk of recurrent clinical disease in some patients, accompanied by severe fatigue and reappearance of bone pain and other skeletal manifestations of untreated Gaucher disease [10,30-33].

Exploratory analysis of the key secondary efficacy endpoints (spleen volume, hemoglobin concentration and platelet count) were included in the trial design after the primary endpoint was agreed with the EMA, based on their scientific relevance. Overall, these secondary endpoints indicated stable disease between baseline and the end of miglustat treatment. High proportions of patients who were within therapeutic goals for each parameter at baseline were maintained within goal up to Month 24.

The clinical relevance of the absolute mean changes in secondary efficacy parameters, most of them in the direction of disease progression, is difficult to interpret. The mild baseline disease burden of the study population should be taken into account. For instance, the 102 mL increase in spleen volume in non-splenectomized patients at end of treatment should be considered in the context of the low mean absolute baseline value of 510 mL, compared with values normally seen in long-term enzyme therapy patients. In all, 8/30 (27%) patients showed clinically relevant increases in spleen volume.

Small mean absolute reductions in hemoglobin were observed during miglustat therapy (-0.95 g/dL from a baseline of 14.8 g/dL). Four out of 41 (10%) patients had clinically relevant decreases in hemoglobin indicative of disease progression but, as with the organ volume findings, the great majority (94%) of patients was maintained within the normal range. The proportion of patients remaining stable for platelet count (85%) from baseline to Month 24 was slightly lower than for other key parameters, with an absolute mean change of -44.1 × 10⁹/L. Nine of 41 (22%) patients had decreased platelet counts that were considered potentially relevant.

The relevance of plasma chitotriosidase for monitoring disease status in patients with stable, mild type 1 Gaucher disease after switching to miglustat in relation to prognosis is currently unclear. Consistent with other systemic disease parameters, the median absolute chitotriosidase activity was low at baseline (963 nmoles/[mL*hr]) but was variable between patients despite long-term enzyme therapy. Changes in chitotriosidase activity in response to miglustat treatment were also highly variable, with some patients showing marked increases; this suggests that these patients had ‘subclinical’ disease progression, which was unassociated with clinical events. Miglustat has been shown to significantly reduce plasma chitotriosidase activity in treatment-naïve patients over 3 years of therapy [13,14]. In the previous open-label randomized study reported by Elstein et al. [19], mean chitotriosidase activity remained stable during miglustat therapy in 27/28 (96%) patients with type 1 Gaucher disease after switching from long-term enzyme therapy. Similar findings were reported in the Spanish ZAGAL cohort study [16].

Bone pain (rated on a visual analogue scale ranging from 0 to 100) was unchanged during 24 months of miglustat treatment, and none of the 17 evaluable patients who were free of bone pain at baseline experienced pain episodes throughout follow up. MRI-based BMB scores indicated a slight increase in bone marrow infiltration over 24 months. Again, this may indicate subclinical disease progression in some patients. Of note, there was no median change in BMB score among the six splenectomized patients, compared with the small median change (+3) among the 15 patients with intact spleens. Previously, stable BMB scores have been
observed for up to 18 months in patients changed from enzyme therapy to miglustat [34]. Long-term follow up in a Spanish cohort of switch patients showed an improvement in lumbar spine bone marrow infiltration during 48 months of therapy [16].

It is not possible to discern whether patient genotype had an influence on the changes in these disease parameters, due to the small sample size. From the genotype data presented in Table 3 there does not appear to be any clear association of a particular genotype with disease worsening or improvement during miglustat therapy.

To ensure the safety of patients who might show deterioration, we used conservative exploratory criteria to identify patients with ‘suspected disease worsening’ after switching from a stable dose of enzyme therapy to miglustat. These criteria do not reflect those generally used in clinical practice [35]. Based on the criteria defined in the trial protocol, miglustat treatment was discontinued in a total of six patients, as adjudicated by the Steering Committee. The number of patients finally adjudicated as exhibiting disease worsening (n = 13) was lower than the total number of cases with suspected disease worsening referred by investigators during or at the end of the study (n = 20). This may be related to the fact that decision making regarding disease worsening during the study was based on local readings, while the Steering Committee utilized both local readings and standardized central readings at the end of the study.

No new or unexpected safety findings came to light during this 24-month study and, overall, the safety and tolerability of miglustat was found to be consistent with its known safety profile [11,13-15,19,36]. Gastrointestinal effects such as diarrhea and flatulence were the most frequently reported adverse events, and were the most frequent reason for premature discontinuation of therapy. In this respect, it is regrettable that firm guidance for avoiding or ameliorating gastrointestinal disturbances, such as dietary modification in the early phase of treatment, was not specified in the study protocol. Such interventions during the initial weeks of miglustat therapy can substantially improve tolerability [37,38]. Notably, patients attending the one center where individual dietary guidance was provided reported the least severe gastrointestinal side effects.

No new cases of peripheral neuropathy with clinical symptoms attributable to miglustat occurred in the present study. The observed 11.9% prevalence of neuropathy at baseline is in agreement with the prevalence of peripheral neuropathy (11%) reported in a previous study of 103 type 1 Gaucher disease patients not receiving this agent [4]. Findings from the neuropsychological assessments conducted in this study were in line with data from the miglustat post-marketing surveillance program [36].

To an extent, the current study allows a limited interpretation of the therapeutic role of miglustat in Gaucher disease. The wide variability in response between patients included in this study, alongside the appreciable rate of premature discontinuations from therapy, suggest that the use of miglustat as a maintenance therapy in GD1 might be suitable for a distinct group of patients. However, additional data would be required to fully define such a group.

With regard to the higher than expected patient dropout from this study, it seems likely that the stringent criteria we adopted to define ‘disease worsening’ may have contributed to their withdrawal. However, we defend the rigorous adjudication process because of the need to ensure that no patient experienced unnecessary or untoward deterioration during the protracted (2-year) course of the trial. The criteria that were adopted for withdrawing patients from this study do not reflect those that are used in therapeutic decision-making regarding treatment failure in clinical practice. Finally, while an examination of the achievement of therapeutic goals was included in the statistical analysis plan, it was not defined a priori, and thus should be interpreted with caution. In addition, such an analysis may lack sensitivity, as it is possible that patients experiencing deterioration in a particular disease parameter could still remain within the range for the goal.

**Conclusions**

The primary efficacy endpoint was met; overall there was no change in liver volume during 24 months of miglustat therapy. However, a notable proportion of patients showed a gradual deterioration in some disease manifestations, suggesting that miglustat could maintain clinical stability, but not in all patients. Miglustat demonstrated a predictable profile of safety and tolerability that was consistent with that reported in previous clinical trials and experience in clinical practice. Gastrointestinal tolerability was identified as an important clinical management issue in this study and should be actively addressed, particularly during the early weeks of miglustat therapy.

**Appendix**

*Miglustat Maintenance Study Group investigators and patient numbers per center:* Amato D, Toronto, Canada (n = 5); Belmatoug N, Paris, France (n = 1); Cox TM, Cambridge, UK (n = 6); Fernhoff P, Decatur, USA (n = 3); Giraldo P, Zaragoza, Spain (n = 2); Giugliani R, Porto Alegre, Brazil (n = 1); Hollak CEM, Amsterdam, the Netherlands (n = 3); Hwu W-L, Taipei, Taiwan (n = 1); Malinová V, Prague, Czech Republic (n = 2); Packman S, San Francisco, USA (n = 1); Pastores G, New York, USA (n = 3); Rhead WJ, Wauwatosa, USA
(n = 3); Rowell J, Herston, Australia (n = 1); Steiner RD, Oregon, USA (n = 6); Szer J, Carlton, Australia (n = 2); Tifft-Rosenbaum K, Washington DC, USA (n = 2).

Competing interests

TMC has received unrestricted research funding from Cambridge in America, Genzyme Corporation and Shire Human Genetic Therapies, and has received consulting fees from (not retained) from Genzyme Corporation, Shire Human Genetic Therapies and Actelion Pharmaceuticals. He has also received honoraria for investor consultation from Genzyme Corporation, and has provided expert advice on legal proceedings related to neglected treatment of acute porphyria. DA has received research and operating grants, honoraria for speaking, and travel funds from Actelion Pharmaceuticals, Genzyme Corporation, Protalix Biopharmaceuticals, and Shire Human Genetic Therapies. CEMH has received consultation fees from Actelion for participation in clinical trial programs and other projects, and speaker fees for participation in scientific congresses and sponsored events. CEMH donates all fees to the Gaucher Stichting, a national foundation that supports research in the field of lysosomal storage disorders. RDS has received research grants from TKT/Shire, honoraria for speaking and consulting, travel funds from Actelion Pharmaceuticals, and honoraria from Genzyme, Biomatrin, Amicus, and Shire Human Genetic Therapies. CL is an employee and stockholder at Actelion. MS and RG were employees at Actelion at the time this research was performed.

Authors’ contributions

TMC was the principal clinical investigator. DA, CEMH and RDS were participating clinical investigators. All clinical investigators were involved in the recruitment and treatment of patients and the provision of raw clinical data. RG was the International Clinical Leader of the trial at Actelion, providing oversight of all aspects of trial conduct and data analysis. CL was the Scientific trial leader at Actelion and provided overall trial management. MS at Actelion planned and conducted the statistical analysis of the trial data. All authors have reviewed and interpreted the data, reviewed each draft of the manuscript and approved the final version for submission.

Acknowledgements

The authors would like to thank the investigators of the Miglustat Maintenance Study Group for their valuable contributions; a complete list of the members of the Miglustat Maintenance Study Group appears in the Appendix A. We are also grateful to the Steering Committee members (Dr. Atul Mehta, Derralyn Hughes, Stephan vom Dahl, Claus Nierau and David Kuter) for their work in this study adjudication process. The authors gratefully acknowledge Linda Pavis at SYNARC, Sévres, France for central assessment of organ volumes and BMM scores, Dr Ivo van Schaik at the Academic Medical Center, Amsterdam, the Netherlands, for central assessments of neurological safety endpoints, and Patricia Paesold-Burda at the Kinderspital Zürich, Switzerland, for conducting the central laboratory assessments of biomarkers. This work was supported by Actelion Pharmaceuticals Ltd. Matthew Reilly PhD, associated with InTouch Medical Ltd, provided medical writing assistance in the preparation of this manuscript, funded by Actelion Pharmaceuticals Ltd.

Author details

1 University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK. 2 Mount Sinai Hospital, University of Toronto, Toronto, Canada. 3 Academic Medical Centre, Amsterdam, The Netherlands. 4 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. 5 Child Development and Rehabilitation Center/Doebercher Children’s Hospital, Oregon Health & Science University, Portland, OR, USA.

Received: 14 May 2012 Accepted: 7 December 2012 Published: 27 December 2012

References

1. Brutter E, Grabowski GA: Gaucher disease. In The metabolic and molecular basis of inherited disease. 8th edition. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1995:3635–3668.
2. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Misty P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A: The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000, 160:2835–2843.
3. Cox TM, Schofield JP: Gaucher disease: clinical features and natural history. Ballifres Clin Haematol 1997, 10:557–689.
4. Biegstraaten M, Mengel E, Marold L, Petakov M, Niederau C, Giraldo P, Hughes D, Mirsch M, Mehta A, Hollak CE, van Schaik IN: Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain 2010, 133:2900–2919.
5. Sidransky E: Gaucher disease: complexity in a "simple" disease. Mol Genet Metab 2004, 83:6–15.
6. Zimran A, Alarcon GS, Phillips M, Attias D, Jomidiak M, Deeb M, Wang N, Birangi K, Cohn GM, Etienne D: Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010, 115:4651–4656.
7. Etienne D, Zimran A: Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics 2009, 3:407–417.
8. Starzyk K, Richards S, Yee J, Smith SE, Kingma W: The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 2007, 90:157–163.
9. Brooks DA, Kapavaro R, Hopwood J: Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 2003, 9:450–453.
10. Giraldo P, Kun P, Alfonso P, Dalmau J, Fernandez-Galan MA, Figueredo A, Hernandez-Rivas JM, Julia A, Luno E, Marin-Irmenz E, et al: Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis 2011, 46:115–118.
11. Actelion zavesca® (miglustat capsules) prescribing information. 2010: Available at: http://www.zavesca.com/pdf/zavesca_pip.pdf. Accessed 9 June, 2011.
12. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebieck M, Platt F, Butters T, Dwek R, Moysey C, et al: Novel oral treatment of Gaucher’s disease with N-butyldeoxyxojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000, 355:1481–1485.
13. Etienne D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM, Lachmann RH, Hrebieck M, Platt FM, Butters TD, et al: Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxyxojirimycin, OGT 918) in type 1 Gaucher disease. J Inherit Metab Dis 2004, 27:575–576.
14. Heathr R, Etienne D, Aerts J, Weely S, Zimran A: Low-dose N- butyldeoxyxojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002, 28:127–133.
15. Pastores GM, Barnett NL, Kolodny EH: An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005, 27:1215–1227.
16. Giraldo P, Alfonso P, Atubka K, Fernandez-Galan MA, Barez A, Franco R, Alonso D, Martin A, Late P, Pocovi M: Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project. Haematologica 2009, 94:1771–1775.
17. Giraldo P, Late P, Alfonso P, Acero A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher’s disease. Haematologica 2006, 91:703–706.
18. Pastores GM, Etienne D, Hrebieck M, Zimran A: Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther 2007, 29:1645–1654.
19. Etienne D, Dweck A, Attias D, Hadas-Halpern I, Zevin S, Attarasan G, Aerts JF, van Weely S, Zimran A: Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007, 110:2296–2301.
20. Maas M, van Kuijk C, Stoker J, Hollak CE, Akkerman EM, Aerts JF, den Heeten GJ: Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging–initial experience. Radiology 2003, 229:554–561.
21. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Misty PK, Tylki-Szymanska A: Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004, 41:4–14.
22. Merkies IS, Schmitz PI, Van der Meche FG, van Doorn PA: Psychometric evaluation of a new sensory scale in immune-mediated polymyopathies, Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000, 54:945–949.
23. Kleyweg RP, van der Meche FG, Schmitz PI: Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991, 14:1103–1109.

24. Donofrio PD, Albers JW: AAEM minimonograph #34: polynuropathy: classification by nerve conduction studies and electromyography. Muscle Nerve 1990, 13:889–903.

25. Wesnes KA, Ward T, McGinty A, Petrini O: The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 2000, 152:353–361.

26. Wesnes KA: The value of assessing cognitive function in drug development. Dialogues Clin Neurosci 2000, 2:183–202.

27. Bond A, Lader M: The use of analogue scales in rating self-rated feelings. Br J Med Psychol 1974, 47:211–218.

28. Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, Balicki D, Vaughan L: The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis 1995, 21:86–108.

29. de Fost M, Aerts JM, Groener JE, Maas M, Akkerman EM, Wiersma MG, Hollak CE: Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica 2007, 92:215–221.

30. Grinzaid KA, Geller E, Hanna SL, Elsas LJ 2nd: Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002, 4:427–433.

31. Toth J, Erdos M, Marodi L: Rebound hepatosplenomegaly in type 1 Gaucher disease. Eur J Haematol 2003, 70:125–128.

32. Hollak CE, Vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deeghan P, Van Dussen L, Girald P, et al: Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010, 44:41–47.

33. Zimran A, Altarescu G, Einstein D: Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply. Blood Cells Mol Dis 2011, 46:111–114.

34. Mikosch P, Reed M, Baker R, Holloway B, Berger L, Mehta AB, Hughes DA: Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat. Calcif Tissue Int 2008, 83:43–54.

35. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HI, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 2005, 80:223–229.

36. Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B: Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoeconom Drug Saf 2009, 18:770–777.

37. Belmatoug N, Birluna A, Giraldo P, Hendrikz CJ, Kuter DJ, Mengel E, Pastores GM: Gastrointestinal disturbances and their management in miglustat-treated patients. J Inherit Metab Dis 2011, 34:991–1001.

38. Champion H, Ramaswami U, Imrie J, Lachmann RH, Gallagher J, Cox TM, Wraith JE: Dietary modifications in patients receiving miglustat. J Inherit Metab Dis 2010, doi:10.1007/s10545-008-0923-9. Epub ahead of print.